查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827977

血糖監測設備市場（按設備類型、技術、應用、最終用戶和分銷管道）—全球預測 2025-2032

Glucose Monitoring Devices Market by Device Type, Technology, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年血糖監測設備市場將成長至 217.4 億美元，複合年成長率為 12.85%。

主要市場統計數據
基準年2024年 82.6億美元
預計2025年 93.4億美元
預測年份：2032年 217.4億美元
複合年成長率（%） 12.85%

全面了解不斷發展的血糖監測格局、技術進步、臨床採用模式和相關人員的優先事項

血糖監測領域正在經歷快速的技術和商業性變革，重塑臨床醫生、看護者和糖尿病患者的血糖監測方式。感測器小型化、數據連接和演算法分析方面的進步與護理路徑的轉變相融合，為慢性病管理創造了新的模式。本簡介將核心促進因素和框架假設進行綜合，為更深入的分析奠定基礎，涵蓋市場動態、細分市場、區域差異和策略影響。

近年來，人們的關注點已從偶爾的指尖採血檢測轉向持續的即時監測模式，這種模式強調縱向數據和可操作的洞察。這種轉變影響著設備設計、監管策略、報銷參與度和最終用戶體驗。結果是，競爭環境日益激烈，老牌醫療設備製造商、專業的糖尿病技術公司和新興的數位健康公司都在製定強調連結性、易用性和臨床整合的提案。當相關人員考慮產品開發、臨床證據產生和商業化路徑時，清楚了解技術趨勢和監管壓力對於抵禦短期衝擊並實現持續應用至關重要。

深入探討技術、監管和商業性變革的融合，重新定義血糖監測的產品價值和照護途徑

一系列相互關聯的變革正在重塑血糖監測領域，這些變革正在重新定義產品價值、護理服務和競爭優勢。感測器精度的提升，加上更長的佩戴時間和微創的外形規格，正在將應用場景從傳統的糖尿病管理擴展到預防性監測和手術全期護理。同時，可互通的資料生態系統和雲端原生分析正在賦能遠端監測、人口健康管理和決策支援等領域的全新服務，從而改變著設備製造商和軟體合作夥伴的期望。

監管機構正在不斷發展，以適應軟體和自適應演算法作為醫療設備的應用，這增加了真實世界證據和上市後監管的重要性。付款方的支付方式也在發生變化，基於價值的基本契約和基於結果的報銷模式在某些市場越來越受歡迎。這種系統性轉變正迫使企業將其臨床證據策略與商業模式結合，並投資於硬體、軟體和服務的跨學科能力。因此，隨著市場的成熟，那些整合以使用者為中心的設計、強大的臨床檢驗和可擴展資料基礎設施的領導者將擁有更優越的策略選擇。

從策略角度評估 2025 年關稅變化如何改變整個血糖監測價值鏈的供應鏈、採購決策和商業策略

2025年新關稅的實施對整個血糖監測生態系統的供應鏈、籌資策略和定價決策產生了一系列連鎖反應。依賴國際採購零件的製造商面臨到岸成本上升的問題，導致許多製造商重新評估其採購佈局和供應商多元化。對於在受影響國家以外擁有垂直整合製造業務的公司來說，關稅環境激勵他們加快在地化和區域供應商開發，以確保生產的連續性並管理單位經濟效益。

除了直接成本壓力外，關稅還影響了產品組合和採購時機的策略選擇。一些公司優先考慮利潤率較高的訂閱式服務和捆綁產品，以保護收益流免受設備價格暫時下跌的影響。醫療保健機構和大型採購商的應對措施是更新其採購框架，將整體擁有成本（而不僅僅是關鍵單位成本）納入考慮。同時，由於製造商尋求記錄產品來源和合規性，監管備案和供應鏈認證變得更加重要，這增加了產品上市的專案成本。累積效應是商業策略的重新平衡，轉向彈性、供應商冗餘以及產品藍圖與採購風險接受度的更緊密結合。

細粒度細分整合揭示了設備類型、技術選擇、臨床使用、最終用戶設定和分銷管道如何決定差異化創新和上市方法

透過對設備類型、技術、應用、最終用戶和分銷管道進行細分分析，可以揭示差異化的創新軌跡和應用趨勢。依裝置類型分類，連續血糖監測和閃光血糖監測與自我監測形成對比，而自我監測本身又根據臨床工作流程和付款人要求分為個人型和專業型。侵入式方法（包括比色法和電化學安培法）繼續與以皮下感測器為主導的微創方法以及利用光譜和經皮提取的非侵入式方法共存，每種方法都呈現出其獨特的監管格局和用戶體驗權衡。

基於應用的細分強調，設備設計和服務模式是根據妊娠糖尿病護理、1 型糖尿病管理和 2 型糖尿病患者的需求量身定做的，臨床證據和教育支持也隨之變化。最終使用者細分將需求分為門診、居家醫療環境，醫院進一步分為私立和公立機構，具有不同的採購限制和臨床通訊協定。最後，分銷管道的差異決定了商業化策略，醫院藥局、網路商店（包括企業網站和電子商務平台）和零售藥局（由連鎖店和獨立商店組成）實現了多樣化的市場方法。總之，這些細分強調了產品設計、證據產生和商業性執行需要與目標客戶群的需求和限制緊密結合。

區域資訊簡報，解釋地理管理體制、付款人結構和醫療保健提供模式如何為血糖監測的採用創造不同的途徑

區域動態對監管途徑、報銷模式和採用率有著重大影響，從而在美洲、中東和非洲以及亞太地區形成了不同的戰略要務。在美洲，臨床醫生主導的採用和早期付款人的參與推動了先進監測解決方案的快速普及，並強調與電子健康記錄和遠端監測平台的互通性。這種環境有利於那些能夠無縫融入臨床工作流程、展示臨床結果並適應複雜報銷框架的供應商。

歐洲、中東和非洲環境複雜多樣，監管環境、公共採購慣例和醫療體系各自為政，因此需要製定靈活的上市計劃，以適應各國在核准時間和付款人期望方面的差異。與當地經銷商和臨床醫生的夥伴關係通常對於建立信任和調整證據包以適應當地標準至關重要。亞太市場頻譜差異很大，競爭激烈的都市區更青睞支持遠端醫療的解決方案，而價格競爭激烈的市場則強調具有成本效益的設備和可擴展的市場競爭模式。在所有地區，監管協調工作和跨境資料管治討論將繼續影響商業化策略和產品設計重點。

競爭格局評估，確定策略舉措、聯盟模式和能力差距，以決定血糖監測生態系統的領導地位

血糖監測領域的競爭態勢呈現混合格局，既有現有的醫療設備製造商，也有專業的糖尿病技術公司，以及帶來軟體和數據能力的跨產業參與企業。領先企業正大力投資感測器效能、使用者體驗和臨床證據，以捍衛其差異化地位；而敏捷的挑戰者則專注於顛覆性的外形規格、定價模式和軟體賦能服務。競爭中普遍存在的策略舉措包括：感測器和分析能力的垂直整合、擴大與支付方和醫療系統的夥伴關係，以及旨在加快互補技術上市時間的定向收購。

成功的公司將是那些能夠平衡強大的臨床檢驗與可擴展生產，並擁有清晰的商業化路徑以滿足醫療服務提供者、付款人和患者需求的公司。硬體團隊和演算法開發人員之間的協同開發是提供有意義的洞察而非原始數據的先決條件。此外，與分銷合作夥伴和數位健康平台的有效合作將提升覆蓋範圍和依從性，尤其是在居家照護環境中。隨著行業的發展，協調跨職能能力並展示實際影響力的能力將決定哪些公司能夠獲得領導地位。

為製造商和相關人員提供實用的優先建議，以協調臨床檢驗、商業化模式和營運彈性，實現永續優勢

行業領導者應優先考慮一系列切實可行的行動，使產品開發、證據生成和商業化執行與不斷變化的臨床和付款人期望一致。首先，投資於將設備性能與患者和醫療保健系統有意義的結果聯繫起來的臨床研究，對於支持報銷對話和實現產品差異化至關重要。為了補充臨床證據，公司應開發模組化的商業模式，將設備、資訊服務和教育支援結合起來，以增強用戶黏性並實現收益來源多元化。

在營運方面，企業必須透過供應商多元化、生產靈活性以及清晰的零件來源可追溯性來增強供應鏈的韌性。與數位健康平台和電子健康記錄提供者建立策略夥伴關係，將加速其與臨床工作流程的整合，並提升供應商感知價值。最後，企業必須建立上市後資料分析和自適應軟體法規合規能力，以實現迭代改進和持續的法規合規性。將這些行動結合起來，將使企業能夠抓住需求，同時管理不同市場的成本和監管壓力。

用於評估設備技術、臨床應用和商業動態的研究設計、資料來源和分析方法的透明描述

本研究結合了原廠藥和二手資料，旨在對血糖監測現況進行嚴格且可重複的評估。原廠藥包括對臨床醫生、採購主管和技術高管的結構化訪談，並輔以臨床環境下的技術檢驗和觀察性評估，以支持關於可用性和整合挑戰的論述。二手資料研究則使用了同行評審的臨床文獻、監管文件和公開文件，建構了關於技術性能和監管趨勢的堅實證據基礎。

我們的分析方法結合了定性編碼和訪談資料的主題綜合，以確定反覆出現的策略重點；我們的技術評估則根據準確性、穿戴式性和資料互通性等臨床標準對感測器模式進行了評估。我們透過跨多個資訊來源的三角測量檢驗了相關說法，並注意標記尚未出現證據的領域。我們承認這種方法有局限性，包括不同地區臨床實踐的差異以及技術創新的快速發展，這些因素可能會改變研究週期之間的競爭動態。在適當的情況下，我們建議進行能夠反映可靠​​證據範圍的研究，並強調進行有針對性的一手研究以減少不確定性的機會。

策略整合強調綜合技術、證據和商業策略將如何決定哪些組織將創新轉化為持續的臨床和商業性影響

結論總結了報告的核心主題，並強調了對尋求駕馭不斷發展的血糖監測領域的相關人員的策略意義。技術創新正在實現更豐富、更連續的資料集，從而支持更主動的慢性病管理，但要實現這一願景，需要臨床檢驗、監管策略和付款人參與之間的協調。成功將卓越硬體與擴充性數據分析和以用戶為中心的設計相結合的市場參與企業，預計將在醫療保健領域實現廣泛應用。

鑑於地緣政治和貿易中斷會影響成本和供應的連續性，營運韌性和靈活的商業化模式同樣重要。區域差異將持續存在，需要本地證據以及與臨床醫生和採購機構的合作。最終，競爭的勝負將取決於能否展示可衡量的臨床和經濟價值，同時為最終用戶提供直覺、流暢的體驗。果斷採取行動應對這些優先事項的組織將最有能力將創新轉化為對患者和系統層面有意義的成果。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 連續血糖監測儀整合先進的機器學習演算法，用於預測血糖管理
  • 採用無痛、無需校準的非侵入式光學感測技術
  • 將穿戴式 CGM 設備無縫連接到遠端醫療平台和遠端患者監護
  • 設備製造商與數位治療公司建立策略聯盟，以加強糖尿病護理
  • 監管部門的核准加速了植入式長期連續血糖監測系統的開發
  • 對支援多供應商數據標準化的可互通血糖值監測平台的需求不斷成長

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

8. 血糖監測設備市場（依設備類型）

  • 持續血糖監測
    • 個人的
    • 商用
  • Flash血糖監測
  • 自我監測血糖

9. 血糖監測設備市場（依技術）

  • 侵入性
    • 比色分析
    • 電化學安培法
  • 微創
    • 皮下感應器
  • 非侵入性
    • 光譜學
    • 經皮提取

第 10 章血糖監測設備市場（按應用）

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第 11 章 血糖監測設備市場（依最終用戶）

  • 門診治療
  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院

第12章血糖監測設備市場（依通路）

  • 醫院藥房
  • 網路商店
    • 公司網站
    • 電商平台
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

13. 血糖監測設備市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章血糖監測設備市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血糖監測設備市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Abbott Laboratories
    • Dexcom, Inc.
    • Medtronic plc
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Ascensia Diabetes Care Holdings AG
    • Senseonics Holdings, Inc.
    • ARKRAY, Inc.
    • Nipro Corporation
    • Sinocare, Inc.
Product Code: MRR-436B79517C57

The Glucose Monitoring Devices Market is projected to grow by USD 21.74 billion at a CAGR of 12.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.26 billion
Estimated Year [2025] USD 9.34 billion
Forecast Year [2032] USD 21.74 billion
CAGR (%) 12.85%

A comprehensive orientation to the evolving glucose monitoring landscape that frames technological advances, clinical adoption patterns, and stakeholder priorities

The landscape of glucose monitoring is undergoing rapid technological and commercial change, reshaping how clinicians, caregivers, and people with diabetes monitor glycemic control. Advances in sensor miniaturization, data connectivity, and algorithmic analytics are converging with shifting care pathways to create new models for chronic disease management. This introduction synthesizes core drivers and framing assumptions to set the stage for deeper analysis across market dynamics, segmentation, regional variation, and strategic implications.

In recent years, the focus has moved from episodic fingerstick testing toward continuous and real-time monitoring paradigms that emphasize longitudinal data and actionable insights. This transition has implications for device design, regulatory strategy, reimbursement engagement, and end-user experience. The result is a competitive environment where incumbent medical device manufacturers, specialized diabetes technology firms, and emerging digital health players are adjusting their propositions to emphasize connectivity, ease of use, and clinical integration. As stakeholders deliberate product development, clinical evidence generation, and commercialization pathways, a clear understanding of technological trends and regulatory pressures will be essential to navigate near-term disruptions and unlock sustained adoption.

An in-depth look at the converging technological, regulatory, and commercial shifts that are redefining product value and care pathways in glucose monitoring

The glucose monitoring sector is being transformed by a set of interrelated shifts that are redefining product value, care delivery, and competitive advantage. Sensor accuracy improvements combined with extended-wear and minimally invasive form factors are expanding use cases beyond conventional diabetes management into preventive monitoring and perioperative care. At the same time, interoperable data ecosystems and cloud-native analytics are enabling new services around remote monitoring, population health management, and decision support, which in turn alter expectations for device manufacturers and software partners.

Regulatory pathways are evolving to accommodate software as a medical device and adaptive algorithms, increasing emphasis on real-world evidence and post-market surveillance. Payer approaches are also changing, with value-based agreements and outcomes-based reimbursement models gaining traction in selective markets. These systemic shifts pressure firms to align clinical evidence strategies with commercial models and to invest in cross-disciplinary capabilities spanning hardware, software, and services. Consequently, leaders who integrate user-centered design, robust clinical validation, and scalable data infrastructures will capture outsized strategic options as the market matures.

A strategic appraisal of how tariff changes in 2025 reshaped supply chains, sourcing decisions, and commercial strategies across the glucose monitoring value chain

The imposition of new tariff measures in 2025 created a series of cascading effects on supply chains, sourcing strategies, and pricing decisions across the glucose monitoring ecosystem. Manufacturers relying on internationally sourced components faced increased landed costs, prompting many to re-evaluate sourcing footprints and supplier diversification. For companies with vertically integrated manufacturing outside affected jurisdictions, the tariff environment incentivized accelerated localization or regional supplier development to insulate production continuity and to manage unit economics.

Beyond direct cost pressures, tariffs influenced strategic choices around product configuration and procurement timing. Several firms prioritized higher-margin, subscription-based services and bundled offerings to protect revenue streams from one-time device price compression. Health systems and large purchasers reacted by updating procurement frameworks to incorporate total cost of ownership considerations rather than headline unit cost alone. Meanwhile, regulatory filings and supply chain certifications took on new importance as manufacturers sought to document origin and compliance, increasing programmatic costs for market entry. The cumulative effect has been a rebalancing of commercial playbooks toward resilience, supplier redundancy, and closer alignment between product roadmaps and procurement risk tolerance.

A granular segmentation synthesis revealing how device type, technology choices, clinical application, end-user settings, and distribution channels dictate differentiated innovation and go-to-market approaches

Segmentation analysis reveals differentiated innovation trajectories and adoption contours when examined across device type, technology, application, end user, and distribution channel. When framed by device type, Continuous Glucose Monitoring and Flash Glucose Monitoring contrast with Self Monitoring of Blood Glucose, while Continuous Glucose Monitoring itself bifurcates into Personal and Professional variants that address distinct clinical workflows and payer requirements. Technology distinctions further refine the landscape: Invasive approaches, including Colorimetric and Electrochemical Amperometric techniques, continue to coexist with Minimally Invasive options typified by subcutaneous sensors and Non Invasive modalities that leverage optical spectroscopy or transdermal extraction, each path presenting unique regulatory and user-experience trade-offs.

Application-based segmentation highlights that device design and service models are being tailored to the needs of gestational diabetes care, Type 1 diabetes management, and the larger population living with Type 2 diabetes, with clinical evidence and educational support varying accordingly. End-user segmentation splits demand across ambulatory care settings, home care environments, and hospital settings, where hospitals further divide into private and public institutions with different procurement constraints and clinical protocols. Finally, distribution channel distinctions shape commercialization strategies, with hospital pharmacies, online stores-encompassing company websites and e-commerce platforms-and retail pharmacies, made up of chain and independent outlets, enabling diverse go-to-market approaches. Taken together, these segmentation lenses demonstrate that product design, evidence generation, and commercial execution must be tightly aligned to the needs and constraints of targeted customer cohorts.

A regional intelligence overview explaining how geographic regulatory regimes, payer structures, and healthcare delivery models create distinct pathways for glucose monitoring adoption

Regional dynamics exert a material influence on regulatory pathways, reimbursement models, and adoption rates, producing distinct strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinician-led adoption and early payer engagement have supported rapid uptake of advanced monitoring solutions, with an emphasis on interoperability with electronic health records and remote monitoring platforms. This environment has favored vendors who can demonstrate clinical outcomes and integrate seamlessly into clinician workflows while navigating complex reimbursement frameworks.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory standards, public procurement practices, and health system fragmentation require agile market-entry plans that account for national differences in approval timelines and payer expectations. Partnerships with local distributors and clinicians are often critical to build trust and to adapt evidence packages to local standards. The Asia-Pacific region features a broad spectrum of market maturity, with highly competitive urban centers advancing telehealth-enabled solutions and more price-sensitive markets emphasizing cost-effective devices and scalable distribution models. Across all regions, regulatory harmonization efforts and cross-border data governance debates will continue to shape commercialization strategies and product design priorities.

A competitive landscape assessment that identifies strategic moves, partnership patterns, and capability gaps that determine leadership in the glucose monitoring ecosystem

Competitive dynamics in glucose monitoring are characterized by a mix of established medical device manufacturers, specialized diabetes technology companies, and cross-sector entrants that bring software and data capabilities. Leading players have invested heavily in sensor performance, user experience, and clinical evidence to defend differentiated positions, while agile challengers focus on disruptive form factors, pricing models, and software-enabled services. Strategic initiatives observed across the competitive set include vertical integration of sensor and analytics capabilities, expansion of partnerships with payers and health systems, and targeted acquisitions to accelerate time to market for complementary technologies.

Companies that succeed are those that balance robust clinical validation with scalable manufacturing and a clear commercialization pathway that addresses the needs of providers, payers, and patients. Collaboration between hardware teams and algorithm developers has become a prerequisite for delivering meaningful insights rather than raw data. In addition, effective engagement with distribution partners and digital health platforms enhances reach and adherence, particularly in home care settings. As the industry evolves, the ability to orchestrate cross-functional capabilities and demonstrate real-world impact will determine which companies capture leadership positions.

Practical and prioritized recommendations for manufacturers and stakeholders to align clinical validation, commercialization models, and operational resilience for sustained advantage

Industry leaders should prioritize a set of pragmatic actions that align product development, evidence generation, and commercial execution to evolving clinical and payer expectations. First, investment in clinical studies that link device performance to meaningful patient and health system outcomes will be essential to support reimbursement dialogues and to differentiate offerings. Complementing clinical evidence, firms should develop modular commercial models that combine devices, data services, and educational support to increase stickiness and diversify revenue streams.

Operationally, companies must strengthen supply chain resilience through supplier diversification, manufacturing flexibility, and clear traceability of component origins. Strategic partnerships with digital health platforms and electronic health record providers will accelerate integration into clinical workflows and enhance perceived value among providers. Finally, organizations should build capability in post-market data analytics and regulatory compliance for adaptive software, enabling iterative improvement and sustained regulatory alignment. These combined actions will position firms to capture demand while managing cost and regulatory pressures across diverse markets.

A transparent explanation of research design, data sources, and analytical methods used to evaluate device technologies, clinical adoption, and commercial dynamics

This study synthesizes primary and secondary research approaches to provide a rigorous, reproducible assessment of the glucose monitoring landscape. Primary research included structured interviews with clinicians, procurement leaders, and technology executives, supplemented by technical validations and observational assessments in clinical environments to ground claims about usability and integration challenges. Secondary research drew on peer-reviewed clinical literature, regulatory documents, and public filings to construct a robust evidence base for technology performance and regulatory trends.

Analytical methods combined qualitative coding of interview data with thematic synthesis to identify recurring strategic priorities, while technology assessments evaluated sensor modalities against clinical criteria such as accuracy, wearability, and data interoperability. Care was taken to validate claims through triangulation across multiple sources and to flag areas where evidence remains emergent. Limitations of the approach are acknowledged, including variability in clinical practice across regions and the rapid pace of innovation that can shift competitive dynamics between research cycles. Where appropriate, recommendations reflect the degree of evidentiary confidence and highlight opportunities for targeted primary research to reduce uncertainty.

A strategic synthesis highlighting how integrated technology, evidence, and commercial strategies will determine which organizations convert innovation into durable clinical and commercial impact

The conclusion synthesizes the report's central themes and underscores the strategic implications for stakeholders seeking to navigate the evolving glucose monitoring environment. Technological innovation is enabling richer, continuous datasets that support more proactive chronic disease management, but realizing this promise requires alignment among clinical validation, regulatory strategy, and payer engagement. Market participants that successfully integrate hardware excellence with scalable data analytics and user-centered design will unlock broader adoption across care settings.

Operational resilience and adaptive commercialization models are equally important given geopolitical and trade disruptions that influence cost and supply continuity. Regional nuances will persist, demanding localized evidence and tailored engagement with clinicians and procurement entities. Ultimately, the competitive battleground will be defined by the ability to demonstrate measurable clinical and economic value while delivering an intuitive, low-friction experience for end users. Organizations that act decisively on these priorities will be best positioned to translate innovation into meaningful patient and system-level outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Continuous glucose monitors integrating advanced machine learning algorithms for predictive glycemic management
  • 5.2. Adoption of non-invasive optical sensing technology for pain free and calibration free glucose measurement
  • 5.3. Expansion of wearable CGM devices with seamless connectivity to telehealth platforms and remote patient monitoring
  • 5.4. Strategic partnerships between device manufacturers and digital therapeutics companies to enhance diabetes care
  • 5.5. Regulatory approvals accelerating development of implantable long term continuous glucose monitoring systems
  • 5.6. Rising demand for interoperable glucose monitoring platforms supporting multi vendor data standardization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glucose Monitoring Devices Market, by Device Type

  • 8.1. Continuous Glucose Monitoring
    • 8.1.1. Personal
    • 8.1.2. Professional
  • 8.2. Flash Glucose Monitoring
  • 8.3. Self Monitoring Of Blood Glucose

9. Glucose Monitoring Devices Market, by Technology

  • 9.1. Invasive
    • 9.1.1. Colorimetric
    • 9.1.2. Electrochemical Amperometric
  • 9.2. Minimally Invasive
    • 9.2.1. Subcutaneous Sensors
  • 9.3. Non Invasive
    • 9.3.1. Optical Spectroscopy
    • 9.3.2. Transdermal Extraction

10. Glucose Monitoring Devices Market, by Application

  • 10.1. Gestational Diabetes
  • 10.2. Type 1 Diabetes
  • 10.3. Type 2 Diabetes

11. Glucose Monitoring Devices Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Home Care
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Glucose Monitoring Devices Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Stores
    • 12.2.1. Company Websites
    • 12.2.2. E Commerce Platforms
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. Glucose Monitoring Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glucose Monitoring Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glucose Monitoring Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Dexcom, Inc.
    • 16.3.3. Medtronic plc
    • 16.3.4. F. Hoffmann-La Roche AG
    • 16.3.5. Johnson & Johnson
    • 16.3.6. Ascensia Diabetes Care Holdings AG
    • 16.3.7. Senseonics Holdings, Inc.
    • 16.3.8. ARKRAY, Inc.
    • 16.3.9. Nipro Corporation
    • 16.3.10. Sinocare, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLUCOSE MONITORING DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GLUCOSE MONITORING DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLUCOSE MONITORING DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONIT